Asgard Therapeutics
Last verified 2026-06-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2025-01-01attributed |
| Founded | 2018 |
| Headquarters | Lund, Sweden |
| Industry | biotech |
| Stage | unknown |
| Website | asgardthx.com |
Direct cell reprogramming cancer immunotherapy; EIC Transition 2024 Repro-TIL project
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | grant | $2.7M | undisclosed |
Detected tech stack
bootstrap 5.1.3, jquery 3.7.1, jquery migrate 3.4.1, jsdelivr, litespeed, litespeed cache, mysql, php, slick, wordpress 7.0, wp rocket, yoast seo 27.7
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | asgardthx.com, read 2026-06-05 |
| Description | self-reported | asgardthx.com, read 2026-06-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.